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Abstract
Introduction: Oxytocin might be used therapeutically as an ally to rescue osteopathy resulting from diabetes. However, the in vivo effects 
of oxytocin on marrow adipogenesis in diabetes remain unknown. In this longitudinal study, we aimed to investigate the protective ef-
fects of oxytocin on diabetes-induced marrow adiposity in rabbits using proton MR spectroscopy.
Material and methods: Forty-five female New Zealand rabbits were randomly divided into controls, diabetes, and diabetes treated with 
oxytocin (ip, 0.78 mg/kg) for six months. Marrow fat fraction (FF) was determined by proton MR spectroscopy at baseline, and at three 
and six months. Bone mineral density was measured by dual-energy X-ray absorptiometry. Serum biomarkers, glycolipid metabolism, 
and histological analysis of marrow adipocytes were determined. 
Results: Oxytocin treatment had positive metabolic effects in diabetic rabbits, which was based on the changes in glucose metabolism, 
insulin sensitivity, and lipid profiles. The diabetic rabbits demonstrated dramatic marrow adiposity in a time-dependent manner; at 
three and six months the FF percentage changes from baseline were 10.1% and 25.8%, respectively (all P < 0.001). Moreover, oxytocin 
treatment significantly reversed FF values and quantitative parameters of marrow adipocyte in diabetic rabbits to levels of naive control 
rabbits. Oxytocin improved bone formation marker in diabetic rabbits compared to the saline group. Also, treatment of diabetic rabbits 
with oxytocin significantly mitigated bone deterioration when compared with the saline-treated diabetic group (all P < 0.05). 
Conclusions: Oxytocin appears to alleviate harmful effects of hyperglycaemia on marrow adiposity. Proton MR spectroscopy may be 
a valuable tool, providing complementary information on efficacy assessments. (Endokrynol Pol 2018; 69 (4): 416–422)
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Streszczenie
Wstęp: Oksytocyna może być stosowana terapeutycznie w osteopatii wynikającej z cukrzycy, jednakże jej wpływ in vivo na stłuszczenie 
szpiku kostnego w przebiegu cukrzycy pozostaje niezbadany. Niniejsze badanie przekrojowe ma na celu zbadać ochronne działanie oksy-
tocyny na wywołane cukrzycą stłuszczenie szpiku kostnego u królików przy użyciu protonowej spektroskopii rezonansu magnetycznego.
Materiał i metody: Czterdzieści pięć samic królików nowozelandzkich podzielono losowo na grupę kontrolną, grupę z cukrzycą oraz 
grupę z cukrzycą leczoną oksytocyną (0.78 mg/kg, i.p.) przez sześć miesięcy. Frakcja tłuszczu (ang. fat fraction; FF) szpiku kostnego została 
określona za pomocą protonowej spektroskopii rezonansu magnetycznego na początku badania oraz po trzech i sześciu miesiącach. 
Gęstość mineralną kości zmierzono za pomocą absorpcjometrii promieniowania rentgenowskiego o podwójnej energii. Określono również 
biomarkery surowicy krwi, metabolizm glikolipidów oraz sporządzono analizę histologiczną adipocytów szpiku kostnego.  
Wyniki: Leczenie oksytocyną przyniosło pozytywne efekty metaboliczne u królików z cukrzycą, co stwierdzono na podstawie zmian w me-
tabolizmie glukozy, wrażliwości na insulinę oraz profili lipidowych. Zauważono drastyczny wzrost stłuszczenia szpiku kostnego u królików 
z cukrzycą w sposób zależny od czasu; po trzech i sześciu miesiącach, procentowe zmiany frakcji tłuszczu w stosunku do wartości wyjściowej 
wynosiły odpowiednio 10,1% i 25,8% (wszystkie P < 0.001). Co więcej, leczenie oksytocyną znacząco odwracało wartości frakcji tłuszczu oraz 
ilościowe parametry adipocytów szpiku kostnego u królików z cukrzycą do poziomu królików z grupy kontrolnej. Oksytocyna poprawiała 
marker tworzenia kości u królików z cukrzycą w porównaniu do grupy, której podawano sól fizjologiczną. Ponadto, leczenie oksytocyną królików 
z cukrzycą znacząco łagodziło niszczenie kości w porównaniu do grupy z cukrzycą, której podawano sól fizjologiczną (wszystkie P < 0.05).
Wnioski: Oksytocyna wydaje się zmniejszać szkodliwy wpływ hiperglikemii na stłuszczenie szpiku kostnego. Protonowa spektroskopia 
rezonansu magnetycznego może być cennym narzędziem, dostarczającym uzupełniających informacji na temat oceny skuteczności 
leczenia.  (Endokrynol Pol 2018; 69 (4): 416–422)
Słowa kluczowe: cukrzyca, oksytocyna, stłuszczenie szpiku kostnego, spektroskopia rezonansu magnetycznego
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Introduction
Oxytocin, a neurohypophysial peptide, may have 
a wide variety of physiological and pathological func-
tions, which makes oxytocin and its receptor potential 
targets for drug therapy. Previous studies suggested 
that oxytocin has anti-oxidative, anti-apoptotic, and 
anti-inflammatory potential [1]. Recently, there has 
been accumulating evidence showing that oxytocin may 
promote glucose uptake and improve insulin sensitivity 
via direct and/or indirect effects [1–3]. Moreover, it may 
lead to regenerative changes in diabetic pancreatic islet 
cells [3]. These results strongly suggest that oxytocin 
might be a therapeutic target for treating diabetes.
It is well-established that bone fragility is one of 
the chronic complications of diabetes mellitus. Both 
type 1 and type 2 diabetes are associated with impair-
ment of bone health by altering bone formation, bone 
resorption, bone marrow adiposity, collagen forma-
tion, inflammatory cytokine, and calcium metabolism 
[4, 5]. Marrow fat is a unique fat depot, which has 
the potential to contribute to both local and systemic 
metabolic processes. Although the effect of marrow adi-
pocytes on bone integrity is complex, a growing body 
of evidence suggests that an inverse association exists 
between marrow fat content and skeletal mass in some 
contexts [6–9]. In humans, serum oxytocin is a marker 
of energy availability and may be a mediator of bone 
density, structure, and strength [10, 11]. In preclinical 
studies, several lines of evidence have demonstrated 
that oxytocin has a positive anabolic effect on the bone 
biology [12, 13]. These data suggest that oxytocin might 
be used therapeutically as an ally to rescue osteopathy 
resulting from diabetes. However, the in vivo effect of 
oxytocin on marrow adipogenesis remains unknown 
in animal models. 
Since the interactions between bone and fat are 
complex and new emerging concepts regarding their 
relationship have the potential to transform our thera-
peutic targeting of the skeleton, in this longitudinal 
study, we aimed to investigate the protective effects 
of oxytocin on marrow adiposity using MR spectros-
copy in an alloxan-induced diabetes rabbit model over 
a six-month period. 
Material and methods
Animals and experimental protocol
Forty-five female New Zealand rabbits (five months old, 
weighing 3.50 to 4.34 kg) were used in this study. All 
animals were fed ad libitum and individually housed 
in steel cages in a temperature-controlled environment 
(22 ± 2°C) with 12-h light/dark cycles. After two weeks 
of adaptation, baseline body weight and levels of blood 
glucose were measured. Then, the rabbits were random-
ly divided into three groups (n = 15/group): a control 
group, an alloxan-induced diabetes mellitus group, 
and an oxytocin-treated diabetes mellitus group. The 
oxytocin-treated group received a daily intraperitoneal 
oxytocin injection (0.78 mg/kg, #H-2510, Bachem AG, 
Bubendorf, Switzerland) for six months [12], and the 
controls and diabetes model groups were administered 
saline solution.
To create a long-term diabetic rabbit model, a single 
100-mg/kg dose of alloxan monohydrate (Sigma, St 
Louis, MO, USA) dissolved in 10 mL of sterile saline was 
injected as described elsewhere [14], and non-diabetic 
rabbits were injected with saline. Alloxan-treated rabbits 
have been reported to develop severe hypoglycaemia 
within the first few days after injection [14, 15]. To 
prevent hypoglycaemic shock in the alloxan-treated 
rabbits, at 4, 8, and 12 h following alloxan injection, 
10 ml of sterile filtered 5% pharmaceutical-grade glucose 
in phosphate buffer saline was administered subcutane-
ously. In addition, an oral solution of 20% glucose in the 
drinking water ad libitum was provided for 1–2 days af-
ter confirmation of hypoglycaemia (less than 70 mg/dl). 
Their blood glucose levels were monitored every 1–2 h 
until 12 h post injection. Rabbits’ blood glucose lev-
els were checked two times per day for the first four 
weeks and once weekly thereafter in the morning, and 
their weights were recorded once a week throughout 
the study. Rabbits with fasting plasma glucose levels 
≥ 14 mmol/L during the entire experimental period 
were defined as diabetic and included in this study [16].
Each rabbit was anaesthetised with intravenous 
infusion of 3% sodium pentobarbital (1 ml/kg) via an 
ear vein, and they underwent MR spectroscopy scan-
ning at baseline and at three, and six months after 
alloxan or saline injection. In addition, blood samples 
were collected for biochemical analysis. The rabbits 
were sacrificed with intravenous infusion of over-dose 
sodium pentobarbital (50 mg/kg) to obtain the bone 
specimens. Dual-energy X-ray absorptiometry (DXA) 
was performed to measure bone mineral density (BMD) 
at the L5 vertebral body and right femur, and the left 
femur was used for histopathological examination. The 
Guide for the Care and Use of Laboratory Animals was 
followed, and the study protocols were approved by 
the institutional Animal Experiment Ethics Committee.
MR spectroscopy
MRI exams were performed on a commercial 3 Tesla 
MRI system (Siemens Medical System, Erlangen, Ger-
many). The body volume coil and quadrate knee array 
coil was used for the radiofrequency transmission and 
reception, respectively. The rabbits were anaesthe-
tised as mentioned above, ventrally positioned with 
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hind limbs separated from the trunk to scan the left 
femur. Sagittal, coronal, and axial scout T2-weighted 
images of the left femur were initially acquired for 
positioning a 6 × 6 × 14 mm3 voxel in the cancellous 
bone of the distal femur, respectively. Single voxel MR 
spectroscopy was performed by using point-resolved 
spectroscopy sequence according to the method of Li et 
al [7]. After local shimming and gradient adjustments, 
the acquisition parameters used for MR spectroscopy 
were repetition time (TR) 3000 ms, echo time (TE) 
30 ms, signal average 64 without water suppression, 
and spectral bandwidth 2000 Hz and 1024 data-points. 
The longer TR was to minimise the T1 relaxation effect, 
and the shorter TE was to minimise the T2 decay of 
both fat and water. 
A commercially available imaging workstation was 
used for post-processing of MR spectroscopy data. 
Based on previous studies [7], the bulk methylene 
protons and water were determined to be identifiable 
around 1.30 and 4.65 ppm, respectively. To quantify the 
amplitudes of the desired water and lipid signals, Voigt 
functions were used to fit the peaks in the frequency 
domain. The marrow fat fraction (FF) was defined as 
the relative fat signal amplitude in the percentage of 
total signal amplitude (water and fat), and the FF value 
was calculated according to the following equation: FF 
= [Imethylene/( Imethylene + Iwater)] × 100%, where Iwater and 
Imethylene are the signal amplitudes of water and bulk 
methylene, respectively [8].
BMD measurements
For each rabbit, BMD and bone mineral content of the 
L5 vertebrae and left femur were measured by a Hologic 
Discovery Wi DXA Scanner (Hologic Inc., Bedford, MA, 
USA; version 12.7); specific software for small animal-
scanning mode was used as described elsewhere [7]. 
The BMD value was automatically calculated using the 
bone mineral content of the measured area. 
Biochemical analysis
Serum biochemical markers of bone metabolism includ-
ing bone alkaline phosphatase (BALP; Rabbit BALP 
ELISA Kit) and cross-linked C-telopeptide of type I col-
lagen (CTX-I; Rabbit Cross-laps CTX-I ELISA Kit) were 
measured by an enzyme-linked immunosorbent assay 
(CUSABIO, Wuhan, China) according to the manufac-
turer’s instructions. Serum biochemical examinations 
including fasting glucose, total cholesterol, triglycerides, 
and low- and high-density lipoprotein cholesterol were 
detected using a full automatic biochemical analyser. 
Levels of fasting insulin was assessed using a rabbit 
insulin ELISA Kit (Huamei Biological Engineering Co, 
Ltd., Wuhan, China) according to the manufacturer’s 
instructions. 
Histopathological evaluation 
The left femurs were decalcified by 10% glycerinum-
EDTA for six weeks after fixation, dehydrated with 
concentrated ethanol, and embedded in paraffin wax 
after being washed with xylene. Sagittal sections (5 µm 
thick) were made at the distal femoral region. Sections 
were deparaffinised and stained with haematoxylin-
eosin (H&E). The mean diameter, density, and per-
centage area of marrow adipocytes were quantified 
for each rabbit in six fields randomly selected (400×) 
using Image-Pro Plus 6.0 Scion image software (Scion 
Corporation) as described previously [17]. The sections 
were examined in a blinded manner. 
Statistical analysis
Statistical analyses were performed using SPSS 18.0 (SPSS 
Inc., Chicago, IL, USA). Data are presented as means ± 
standard deviations. Shapiro-Wilk test was performed 
to test the normality distribution of the data. Repeated 
measure two-way analysis of variance was used to com-
pare marrow FF between the groups. Differences in bone 
turnover markers, serum biomarkers, and quantitative 
parameters of marrow adipocytes were evaluated by 
one-way analysis of variance (ANOVA). Post-hoc Bonfer-
roni test was used for post-hoc multiple comparisons, and 
p values of < 0.05 were considered statistically significant. 
Results
Changes in body weights
Of the initial 45 rabbits, 39 completed the whole study, 
whereas one naive control rabbit, three saline-treated 
diabetic rabbits, and two oxytocin-treated rabbits died 
of an adverse reaction to anaesthetics. No significant 
difference was found among the study groups in the 
initial weights. At the end of the experiment, body 
weights were significantly lower in the saline-treated 
diabetic rabbits (ranging from 3.78 to 5.30 kg) than in 
the naive control rabbits (ranging from 3.99–5.65 kg). In 
diabetic rats treated with oxytocin daily for six months, 
the body weight ranged between 3.60 and 5.50 kg with 
a mean value of 4.13 ± 0.60 kg (P = 0.713 vs. the diabetic 
group); however, it was still significantly lower (P = 
0.019) than the control group (Table I). 
Evaluation of glycolipid metabolism
Table I represents the changes in blood glucose 
and insulin levels as well as lipid profiles in the study 
groups. The fasting blood glucose concentration signifi-
cantly increased, whereas fasting blood insulin levels 
significantly decreased in the saline-treated diabetic rab-
bits compared to the naive control group. Conversely, 
treatment of diabetic rabbits with oxytocin significantly 
reduced glucose levels and improved fasting blood 
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insulin concentration when compared with those in 
the saline-treated diabetic group. 
As shown in Table I, levels of plasma triglyceride, 
cholesterol, and low-density lipoprotein increased in 
all diabetic rabbits. In diabetic rabbits treated with oxy-
tocin, serum triglyceride, cholesterol, and low-density 
lipoprotein concentration were lower than the saline-
treated diabetic group; however, the serum triglyceride 
and cholesterol concentration was still significantly 
higher than the untreated control group. No signifi-
cant difference was found in high-density lipoprotein 
concentration among the three groups.
Changes in biomarkers of bone turnover and BMD
Examinations of bone formation marker in the dia-
betic rabbits showed a decrease in serum BALP levels 
compared with the naive controls, and daily oxytocin 
injections could increase levels of BALP. However, bone 
resorption marker CTX-I levels were unaltered in the 
diabetic rabbits, and osteoclast activity was not affected 
by the oxytocin treatment (Table I).
As shown in Figure 1, decreases in the L5 vertebral body 
and femur BMD (P < 0.05 for all) were observed in the 
diabetes group compared with the naive control group, 
which were reversed by oxytocin treatment (P < 0.05). 
Changes in marrow fat content and quantitative 
parameters of marrow adipocytes
The in vivo MR spectroscopy measurements taken 
at each time point allowed the monitoring of the FF 
changes in each rabbit. Figure 1 is a representation of 
the MR spectroscopy scans of a rabbit from each of the 
three groups, done at the different time points. The FF 
values for the saline-treated diabetic rabbits markedly 
increased over the six-month period (Figure 2). The 
FF values from baseline, and months 3 and 6 were sig-
nificantly different when tested by adjusted repeated-
measures ANOVA (P < 0.001 for all). At month 3 of the 
FF percentage changes from baseline were 2.1%, 10.1%, 
and 4.1%, for the naive control, saline-, and oxytocin-
treated diabetic rabbits, respectively, and at month 6 the 
percentage changes from baseline were 4.2%, 25.8%, 
and 5.4%, respectively. There was a significant differ-
ence in FF value between the saline-treated diabetic 
rabbits and naive controls or oxytocin-treated diabetic 
rabbits. No differences in FF measures over time were 
noted within the same time-point between the naive 
controls and oxytocin-treated diabetic rabbits.
Histology images stained with H&E validated the 
MR spectroscopy results. Figure 3 summarises the 
changes in quantitative parameters of marrow adipo-
cytes in the studied groups. Quantitative parameters 
of marrow adipocytes including adipocyte density, 
adipocyte volume, and area percentage of fat cells sig-
nificantly increased in the saline-treated diabetic rabbits 
compared to the naive control animals. Conversely, 
treatment of diabetic rabbits with oxytocin significantly 
reduced quantitative parameters of marrow adipocytes 
when compared with those in the saline-treated diabetic 
group. 
Table I. Changes in body weights, glycolipid metabolism, bone turnover biomarkers, and BMD of the rabbits
Tabela I. Zmiany masy ciała, metabolizmu glikolipidów, markerów obrotu kostnego oraz gęstości mineralnej kości (bone 
mineral density, BMD) królików
Naive control group  
(n = 14)
Saline-treated diabetes group  
(n = 12)
Oxytocin-treated diabetes group 
(n = 13)
Initial weight [kg] 3.97 ± 0.29 4.06 ± 0.20 3.98 ± 0.27
Final weight [kg] 4.93 ± 0.57 4.25 ± 0.50a 4.13 ± 0.60a
Glucose [mmol/L] 5.34 ± 0.57 15.93 ± 0.98a 6.18 ± 0.73a, b
Insulin [mmol/L] 17.15 ± 1.56 8.02 ± 0.81a 14.2 ± 1.03a, b 
Plasma cholesterol [mmol/L] 1.43 ± 0.37 2.28 ± 0.49a 1.77 ± 0.41a, b
Triglyceride [mmol/L] 1.01 ± 0.28 1.60 ± 0.35a 1.21 ± 0.33a, b
LDL-c [mmol/L] 0.28 ± 0.04 0.35 ± 0.05a 0.30 ± 0.05b
HDL-c [mmol/L] 0.41 ± 0.06 0.37 ± 0.08 0.40 ± 0.09
CTX-I [ng/ml] 17.51 ± 2.97 16.83 ± 3.36 17.94 ± 3.98
BALP [mIU/ml] 4.97 ± 0.71 3.85 ± 0.63a 5.14 ± 0.82b
Lumbar spine BMD [mg/cm2] 289 ± 33 266 ± 30a 285 ± 26b
Femur BMD [mg/cm2] 360 ± 38 338 ± 31a 356 ± 35b
Values are expressed as mean ± SD.
aP < 0.05 vs. naive control rabbits; bP < 0.05 vs. saline-treated diabetic rabbits
BALP, bone alkaline phosphatase; BMD, bone mineral density; CTX-I, cross-linked C-telopeptide of type I collagen; HDL-c, high-density lipoprotein cholesterol; LDL-c, 
low-density lipoprotein cholesterol
*P < 0.001 vs. the control group; †P < 0.001 vs. the saline-treated diabetes group (one-way ANOVA followed by Bonferroni post-hoc test)
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Discussion
The list of diabetes-associated complications is extensive 
and involves nearly every organ system, including the 
skeleton, and the area of research on the deleterious 
effects of diabetes on bone homeostasis is still in its 
infancy. Our results are consistent with the existing 
literature, which shows impaired bone formation rather 
than increased bone resorption in T1-diabetic animals 
[18, 19].
Oxytocin-oxytocin receptor signalling network can 
prove to be of great importance in therapeutics and 
drug targeting due to its diverse biological functions. 
In preclinical studies, oxytocin has recently been im-
plicated in bone homeostasis, favouring osteoblastic 
over osteoclastic activity and promoting osteogenesis 
over adipogenesis [12, 20]. However, these data mainly 
resulted from osteoporotic animal models but not dia-
betic animals. Work by Elabd and Altirriba showed that 
oxytocin may represent a promising approach for the 
treatment of diabetes and some of its complications, 
including diabetic neuropathy [2, 21]. Our results are 
consistent with the existing literature that shows the 
lack of a visible suppression of osteoclast activity in 
the oxytocin-treated rabbits, suggesting that oxytocin 
treatment increases osteoblast activity but does not 
alter osteoclast activity [3, 12, 22]. Our data confirm 
these results and provide some additional interesting 
information. We found that oxytocin treatment could 
rescue diabetes-related bone deterioration.
In addition to vascular disruption, enhanced mar-
row adiposity has become a hallmark of the diabetic 
bone phenotype. In the present study, in accordance 
with previous experimental studies [23–25], MR spec-
troscopy findings showed a significant increase in 
marrow fat content in diabetic rabbits when compared 
with the naive control animals. A body of growing 
evidence implicates enhanced marrow adipogenesis 
and cellular changes in the bone marrow in a novel 
mechanistic link between various diabetic second-
ary complications, as observed in both type 1 and 2 
Figure 1. Representative MR spectroscopy. FF = 38.9% in the naive control at month 6 (A); FF = 37.0% and 58.7% in the saline-
treated diabetic rabbit at baseline (B) and month 6 (C), respectively; FF = 36.1% in the oxytocin-treated rabbit at month 6 (D)
Rycina 1. Reprezentatywna spektroskopia rezonansu magnetycznego. FF = 38,9% u królików z grupy kontrolnej w szóstym miesiącu 
badania (A); FF = 37,0% i 58,7% u królika z grupy z cukrzycą, której podawano sól fizjologiczną, odpowiednio na początku badania 
(B) i w szóstym miesiącu badania (C); FF = 36,1% u królika z grupy leczonej oksytocyną w szóstym miesiącu badania (D)
Figure 2. Plots of the marrow fat fraction monitored over time 
for the three groups of rabbits. Data are expressed as mean ± SD 
(n =14, 12, and 13 for the naive controls, saline-, and oxytocin-
treated diabetic rabbits, respectively)
Rycina 2. Wykresy frakcji tłuszczu szpiku kostnego, monitorowane 
w czasie dla trzech grup królików. Dane wyrażono jako średnią ± 
odchylenie standardowe (ang. standard deviation, SD) (n = 14, 12 
i 13 odpowiednio dla grupy kontrolnej, grupy z cukrzycą, której 
podawano sól fizjologiczną oraz grupy z cukrzycą leczonej oksytocyną)
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models of diabetes [6, 26], including three possible 
mechanisms: 1. diabetes results in depletion of stem/ 
/progenitor cells in the bone marrow; 2. diabetes may 
reduce mobilisation of marrow stem cells; and 3. high 
levels of glucose may reduce endothelial and mesen-
chymal progenitor cell numbers that have mobilised. 
Unfortunately, assessment of marrow fat content 
in T1 diabetic patients has yielded less impressive 
results. For example, Slade et al. [27] reported mar-
row adiposity from any site tested (e.g. distal femur, 
proximal tibia, and lumbar spine) was not altered by 
T1-diabetes status. This indicates that further studies 
are warranted to fully understand whether marrow 
adipose tissue is altered during T1 diabetes in larger 
clinical trials.
One of the key findings in the present study is that 
daily injection of oxytocin could completely reverse 
marrow fat expansion seen in alloxan-induced diabetic 
rabbits. One explanation could be that oxytocin might 
suppress the expression of peroxisome proliferator-
activated receptors-γ2, a key regulator of adipocyte 
differentiation. Bone metabolism is the combination of 
bone formation by osteoblasts and bone resorption by 
osteoclasts. Adipocytes and osteoblasts share the same 
precursor cells. An inverse association existing between 
osteogenesis and adipogenesis is well documented, 
and thus controlling the fine balance between the 
two lineages is of great therapeutic significance [28]. 
Another explanation could be that oxytocin can be 
a good choice to increase the insulin levels and 
improve insulin sensitivity by reducing gluco- and 
lipotoxicity [2]. This hypoglycaemic effect of oxytocin 
can potentiate the differentiation and migration of 
bone mesenchymal stem cells by inhibiting glycogen 
synthase kinase-3β to osteoblasts [29], thereby inhibit-
ing marrow adipogenesis. Furthermore, the presence 
of marrow adiposity in diabetic bone is linked to the 
lipotoxic effect on bone cells through the secretion 
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Figure 3. Changes in marrow fat cells in diabetic rabbits treated with oxytocin for 6 months. Representative serial sections of marrow 
fat cells (arrow) stained with haematoxylin-eosin stain (400×) are presented in A1 to A3. For the naive control (A1), few marrow fat 
cells were embedded in the marrow nuclear cells. Diabetic rabbit (A2) exhibited markedly increased marrow fat infiltration and decreased 
trabecular bone. This pathological expansion of marrow fat was restored by oxytocin treatment (A3). The quantitative parameters of fat 
cells are presented in B1 to B3. Values in columns are presented as mean ± SD (n =14, 12, and 13 for the naive controls, saline-, and 
oxytocin-treated diabetic rabbits, respectively)
Rycina 3. Zmiany w komórkach tłuszczowych szpiku kostnego u królików z cukrzycą leczonych oksytocyną przez sześć miesięcy. 
Ryciny A1 do A3 przedstawiają reprezentatywne serie preparatów komórek tłuszczowych szpiku kostnego (zaznaczenie strzałką), 
wybarwionych hematoksyliną i eozyną (400x). W przypadku grupy kontrolnej (A1), kilka komórek tłuszczowych szpiku kostnego zostało 
umieszczonych w jądrzastych komórkach szpiku. Królik z cukrzycą (A2) wykazywał wyraźnie zwiększoną obecność tłuszczu w szpiku 
kotnym oraz zmniejszoną istoty gąbczastej kości. Ten patologiczny rozwój tłuszczu w szpiku kostnym został odwrócony dzięki leczeniu 
oksytocyną (A3). Ilościowe parametry komórek tłuszczowych przedstawiono na rycinach B1 do B3. Wartości w kolumnach zaprezentowano 
jako średnią ± SD (n = 14, 12 i 13 odpowiednio dla grupy kontrolnej, grupy z cukrzycą, której podawano sól fizjologiczną oraz grupy 
z cukrzycą leczonej oksytocyną)
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of fatty acids by adipocytes within the bone marrow, 
and this lipotoxic milieu affects osteoblast function 
and survival [30]. Interestingly, oxytocin has anti-
oxidant and anti-inflammatory effects [3], which in 
turn stimulate mesenchymal stem cells osteogenesis 
at the expense of adipogenesis. This indicates that 
the benefits of preventing lipotoxicity could have 
a substantial influence in the treatment of metabolic 
diseases. 
In conclusion, we have demonstrated that oxytocin 
appears to alleviate harmful effects of hyperglycaemia 
on marrow adiposity in diabetic rabbits. This anti-adi-
pogenic potential of oxytocin may attribute to reduced 
adipocytes density and volume in bone tissue. Proton 
MR spectroscopy may be a valuable tool, providing 
complementary information on efficacy assessments 
for bone metabolic diseases.
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